Finally, leveraging the Genomics of Drug Sensitivity in Cancer (GDSC) (Figure 11E and Table S9) and CTRP databases (Figure 11F and Table S10), we identified compounds whose sensitivity positively correlated with RAD51 expression, suggesting their potential utility for targeting RAD51 in OSCC therapy. This evidence concerns the gene RAD51 and cancer.